Skip to main content
SpringerLink
Log in

PET for Drug Development and Evaluation

  • Book
  • © 1995

Overview

Editors:
  1. D. Comar

    1. Hôpital Neuro-cardiologique, Lyon, France

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Nuclear Medicine (DNUM, volume 26)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (31 chapters)

  3. Miscellaneous

    1. The Disposition of a New Drug Propellant (HFA 134a) in Humans Studied by Fluorine-18 Labelling and Whole-Body γ-Counting

      • Victor W. Pike, Richard J. N. Tanner, Franklin I. Aigbirhio, Christopher A. J. Freemantle, Stephen L. Waters, Brian C. Page et al.
      Pages 341-352

    2. Preclinical Characterisation of Radiolabelled Idoxifene

      • Paul Carnochan, Helen Young, Mahendra Trivedi, Suzanne Eccles, Ben Haynes, Gerry Potter
      Pages 353-360
Back to top

Keywords

About this book

Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations.
The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs.
Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas.

Editors and Affiliations

  • Hôpital Neuro-cardiologique, Lyon, France

    D. Comar

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation